TARRYTOWN, N.Y. and PARIS, Jan. 7, 2019 /PRNewswire/ -- Companies select two clinical-stage bispecific antibodies for ongoing collaboration Regeneron retains full rights to all its other investigational immuno-oncology programs; Sanofi able to independently pursue own immuno-oncology...